PT - JOURNAL ARTICLE AU - Wyllie, David AU - Mulchandani, Ranya AU - Jones, Hayley E AU - Taylor-Phillips, Sian AU - Brooks, Tim AU - Charlett, Andre AU - Ades, Anthony E AU - , AU - Makin, Andrew AU - Oliver, Isabel AU - Moore, Philippa AU - Boyes, John AU - Hormis, Anil AU - Todd, Neil AU - Reckless, Ian TI - SARS-CoV-2 responsive T cell numbers are associated with protection from COVID-19: A prospective cohort study in keyworkers AID - 10.1101/2020.11.02.20222778 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.02.20222778 4099 - http://medrxiv.org/content/early/2020/11/04/2020.11.02.20222778.short 4100 - http://medrxiv.org/content/early/2020/11/04/2020.11.02.20222778.full AB - Background Immune correlates of protection from COVID-19 are important, but incompletely understood.Methods We conducted a prospective cohort study in 2,826 participants working in hospitals and Fire and Police services in England, UK during the pandemic(ISRCTN5660922). Of these, 2,672 were unselected volunteers recruited irrespective of previous SARS-CoV-2 RT-PCR test results, and 154 others were recruited separately specifically because they previously tested positive. At recruitment in June 2020, we measured numbers of interferon-γ secreting, SARS-CoV-2 responsive T cells using T-SPOT® Discovery SARS-CoV-2 kits (Oxford Immunotec Ltd), and antibodies to SARS-CoV-2 proteins using commercial immunoassays. We then described time to microbiologically confirmed SARS-CoV-2 infection, stratified by immunological parameters.Results T cells responsive to the spike (S), nuclear (N) and membrane proteins (M) dominated the responses measured. Using the sum of the spots (responsive cells within each well of 250,000 peripheral blood mononuclear cells) for S, N and M antigens minus the control, the 2,672 unselected participants were divided into those with higher responses (n=669, 25.4%; median 30 spots (IQR 18,54)) and those with low responses (n=2016, 76.7%, median 3 (IQR 1,6)), the cutoff we derived being 12 spots. Of the participants with higher T cell responses, 367 (53%) had detectable antibodies against the N or S proteins. During a median of 118 days follow-up, 20 participants with lower T cell responses developed COVID-19, compared with none in the population with high T cell responses (log-rank test, p=6×10−3).Conclusions Peripheral blood SARS-CoV-2 responsive T cell numbers are associated with risk of developing COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was commissioned by the UK Government Department of Health and Social Care. It was funded and implemented by Public Health England, supported by the NIHR Clinical Research Network (CRN) Portfolio. Oxford Immunotec Ltd did T-SPOT tests at their own cost as part of the study. Department of Health and Social had no role in the study design, data collection, analysis, interpretation of results, writing of the manuscript, or the decision to publish. DW acknowledges support from the NIHR Health Protection Research Unit in Genomics and Data Enabling at the University of Warwick. HEJ, AEA, MH and IO acknowledge support from the NIHR Health Protection Research Unit in Behavioural Science and Evaluation at University of Bristol. STP is supported by an NIHR Career Development Fellowship (CDF-2016-09-018). The views expressed are those of the author(s) and not necessarily those of the NHS, NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:EDSAB-HOME study was approved by NHS Research Ethics Committee (Health Research Authority, IRAS 284980) on 02-Jun-2020 and PHE Research Ethics and Governance Group (REGG, NR0198) on 21-May-2020. All participants gave written informed consent. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on reasonable request to corresponding author.